Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-026-04896-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Marwan Al-Hajeili und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, King Abdulaziz University, Kingdom of Saudi Arabia, Jeddah, 23624, Saudi Arabia. Marwan.alhajeili@gmail.com. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, TOR Serine-Threonine Kinases, Drug Resistance, Neoplasm, Choriocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben.
Abstract (Originalsprache)
Gestational choriocarcinoma represents one of the most curable solid tumors when diagnosed early, with cure rates exceeding 95% using standard chemotherapy. However, a subset of patients develops chemoresistance, leading to treatment failure and poor outcomes. Emerging evidence indicates that aberrant activation of the glycogen synthase kinase-3β (GSK-3β)/mechanistic target of rapamycin (mTOR) signaling axis is strongly associated with chemoresistance through multiple interconnected mechanisms. This review examines the molecular pathways by which GSK-3β and mTOR likely contribute to chemoresistance in gestational choriocarcinoma, including enhanced epithelial-mesenchymal transition (EMT), metabolic reprogramming, immune evasion, autophagy dysregulation, and suppression of apoptosis. We analyze how crosstalk between GSK-3β and mTOR complexes (mTORC1/mTORC2) creates a resistant phenotype that limits the efficacy of conventional cytotoxic agents such as methotrexate, actinomycin D, and etoposide. Importantly, we highlight emerging therapeutic strategies to target this axis, including GSK-3β activators (lithium, 9-ING-41), mTOR inhibitors (rapamycin analogs, dual PI3K/mTOR inhibitors), and combination regimens that synergistically restore chemosensitivity. Preclinical data from trophoblastic and related malignancies demonstrate that dual targeting of GSK-3β and mTOR can reverse resistance phenotypes and enhance treatment responses. This comprehensive review provides a translational framework for developing molecularly targeted therapies in chemoresistant gestational choriocarcinoma, with potential implications for personalized treatment algorithms and clinical trial design in this rare but highly treatable malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, King Abdulaziz University, Kingdom of Saudi Arabia, Jeddah, 23624, Saudi Arabia. Marwan.alhajeili@gmail.com.
- Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad, Iraq.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University- Arish Branch, Arish, 45511, Egypt. ahmed.abdelaziz@su.edu.eg.
- Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhur University, Damanhur, AlBeheira, 22511, Egypt. dr_gaber_batiha@vetmed.dmu.edu.eg.
Zitieren
APA
Al-Hajeili, M., Al-Kuraishy, H. M., Abdelaziz, A. M., & El-Saber Batiha, G. (2026). Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04896-8
Vancouver
Al-Hajeili M, Al-Kuraishy HM, Abdelaziz AM, El-Saber Batiha G. Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04896-8
BibTeX
@article{AlHajeili2026,
author = {Al-Hajeili, Marwan and Al-Kuraishy, Hayder M and Abdelaziz, Ahmed M and El-Saber Batiha, Gaber},
title = {Targeting the GSK-3β/mTOR axis to overcome chemoresistance in gestational choriocarcinoma: molecular mechanisms and therapeutic opportunities},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-026-04896-8}
}
EUVIMED